USC UNIVERSITY OF SOUTHERN CALIFORNIA

HSC WEEKLY

Vol. 6, No. 6 February 18, 2000

Published for the students and employees of the USC Health Sciences Campus

Foundation provides seed money for ovarian cancer research at Norris

Innovative ovarian cancer research spanning detection and treatment is taking place at USC/Norris Comprehensive Cancer Center, thanks to seed money donated by the Los Angeles-based Lynne Cohen Foundation. The donations—to studies that have now shown enough promise to garner major federal funding—highlight the importance of private donations to the steady progress in cancer research.

Started in 1998 by three young sisters in honor of their mother who had recently succumbed to ovarian cancer, the Lynne Cohen Foundation is dedicated to providing start-up funding for research that shows signs of increasing the survival rate for women with the disease.

The funds are designed to act as a springboard to help physicians/scientists conduct pioneering ovarian cancer research that might otherwise never see the light of day. Two of the beneficiaries of the Cohen Foundation's farsighted approach are now showing signs of promise at USC/Norris.

Firstly, ovarian cancer clinical trials for anti-angiogenic compound IM862—a novel drug therapy delivered via a nose drop—are now underway. Secondly, a new test designed to detect hidden ovarian cancer in patients finishing treatment for the disease is now set to undergo a major nationwide NIH-funded trial, after the Foundation provided funding for the early research.

Cancer-killing nose drops may sound like science fiction, but this experimental treatment has already shown highly promising results for a team of USC scientists led by Parkash Gill, in treatment of another form of cancer.

Last year, Gill reported that patients with late-stage Kaposi's sarcoma, an AIDS-related cancer, had complete or partial remission after using nose drops containing a drug that cuts off a tumor's blood supply (a mechanism known as "anti-angiogenesis"). This success prompted the new study looking at IM862's efficacy in treating ovarian carcinoma.

Martin Elbogen

Pausing during a tour of the Norris are, from left: USC/Norris pathologist Louis Dubeau with Foundation President Amy Cohen and Foundation members Whitney Rosenson and Erin Cohen.

Seed money from the Lynne Cohen Foundation has also provided underpinning for the first steps in the development of a new test, known as the Telomeric Repeat Amplification Protocol (TRAP) assay, that may be used to detect residual ovarian cancer cells in patients who appear to have been successfully treated with chemotherapy.

Ovarian cancer is much less common than other gynecological cancers, yet it remains very deadly, proving fatal for around 15,000 women each year. Many women successfully battle the tumor initially, only to have the disease return. Part of the problem is the lack of a sensitive test, or assay, that will pick up the few rogue tumor cells that may remain and proliferate after therapy.

With this in mind, USC/Norris pathologist Louis Dubeau and his colleagues have been working on a new test based on the fact that ovarian cancer cells express abnormally high levels of telomerase. Telomerase is an enzyme critical to cell replication—without it, cells can only divide a set number of times before damaging the chromosomes.

To catch such cancer cells, doctors currently use a "second-look surgery," in which surgeons take biopsies and wash fluids through the abdomen to detect the presence of cancer. Though this procedure is considered the most sensitive available, it often fails to find residual disease. Nearly half of patients who show no sign of disease with the second look go on to develop subsequent tumors.

—Paul Dingsdale

Cancer-fighting nose drops show promise

An anti-angiogenesis drug, delivered as a nose drop, can bring on the death of tumor cells and even result in remission in patients with AIDS-related Kaposi's Sarcoma (KS), according to a study published in the February issue of the *Journal of Clinical Oncology* by researchers from the USC/Norris Comprehensive Cancer Center.

Parkash Gill

This is the first treatment aimed at disrupting the production of new blood vessels to be successful against the most common malignancy associated with the human immunodeficiency virus, for which there is currently no cure.

A total of 44 patients—42 men and 2 women—with KS were enrolled in an open-label Phase I/II trial of IM862, a tiny protein normally made in the thymus gland.

Five of the patients taking the drug experienced a complete remission, and another 11 showed a partial remission, for a major response rate of 36 percent. "And all this occurred with very few side effects, which were limited mostly to mild headaches," said Parkash Gill, professor of medicine and pathology at The Keck School of Medicine and the study's principal investigator.

IM862 not only works, it works quickly: The median amount of time it took for patients in the Phase I/II trials to respond was six to eight weeks. "It can take as much as 20-some weeks to see a complete response," said Gill. "But that's still fairly rapid."

And the drug's response lasts, as well. For 21 of the patients, the stabilization or regression of their disease had lasted for up to 72 weeks when the data were compiled—even after they stopped taking the drug. "We have a number of patients who after stopping therapy have still not relapsed," he noted.

The trial was conducted both at USC/Norris and at Massachusetts General Hospital. Gill first unveiled his findings at the 35th annual meeting of the American Society of Clinical Oncology last May. IM862, a peptide, was developed by Cytran, Inc., of Kirkland, Wash. Its anti-angiogenic effect appears to be the result of a reduction in the production of a hormone called vascular endothelial growth factor (VEGF), said Gill.

VEGF is the hormone responsible for new blood vessel growth in the body. IM862 also appears to have immune system effects, enhancing the production of chemicals like interleukin-12 and thereby kicking into action the body's so-called natural killer (NK) cells.

These two actions are actually quite closely intertwined, Gill noted. "NK cells produce factors that are toxic to endothelial cells," he explains, which means they can slow the growth of blood vessels as well as attack the tumor itself.

Recent laboratory analyses have shown that animals with pancreatic tumors who are treated with IM862 not only have a reduced rate of tumor growth, but have lower levels of VEGF as well. "This confirms quite nicely that at least one of the ways the drugs is working is by anti-angiogenesis," said Gill.

Phase III trials of IM862 are now well underway at the USC/Norris.

In addition, IM862 is currently being tested as a treatment for ovarian cancer, melanoma and colorectal cancer, and Gill and his colleagues are planning to begin a trial for prostate cancer as well.

Anil Tulpule, David T. Scadden, Byron M. Espina, Suzanne Cabriales, Walter Howard, Kathleen Shea, Parkash Gill, "Results of a Randomized Study of IM862 Nasal Solution in the Treatment of AIDS-related Kaposi's Sarcoma." *Journal of Clinical Oncology*, Vol. 18, No. 4, [February] 2000.

—Lori Oliwenstein

Serving the community

Medical students plan free clinic for the homeless

If USC students have their way, what started out small—a proposed volunteer day at a homeless shelter—will actually become a medical lifeline for people without homes.

Second-year medical student Catherine Rongey first approached People Assisting the Homeless (PATH), a Los Angeles-based organization, at the end of 1998 to explore setting up a student volunteer day with the group.

But the group's staff saw a greater need—setting up a clinic for homeless people in their new Westlake-area access center, which will open in 2001. That potential to make a difference in the community prompted Rongey and fellow second-year medical student Jo Persoon-Gundy to propose the USC Free Medical Clinic Project, with the help of supportive faculty members.

"The clinic will serve a population of extraordinary need, whose access to health care is minimal and who have almost no continuity of care," said Persoon-Gundy, who plans to pursue her interests in community health care through emergency medicine. "They are seen in emergency rooms, at various mobile clinics and scattered free

See **CLINIC**, Page 2

Study suggests way to improve managed care of alcoholism treatment

A large number of alcoholics go through detoxification programs under managed care, but a significantly greater percentage of those would participate in effective follow-up treatment if their co-payments were reduced, according to a new study conducted by Bradley Stein, assistant professor of psychiatry, and researchers at the RAND Corporation.

It appears in the February issue of *Psychiatric Services*.

Stein and his colleagues examined data for more than a 1,000 patients from 14 employer groups over seven years from a mid-western managed care company offering behavioral health care benefits.

"It is obvious to expect that lower co-payments would increase participation in effective follow-up treatment, but our study shows that the increase is substantial. Besides, without follow-up treatment, the dollars spent on detoxification alone cannot produce long-term recovery for those with severe addictions," Stein explained.

"Our study showed that almost 79 percent of detoxification patients in managed care received formal substance abuse treatment follow-up, but their participation in these follow-up treatment programs depended on the amount of their co-payments. That suggests there is room for improvement," according to Stein.

An estimated five million Americans need drug and alcohol treatment. The first step in the treatment for many is detoxification, which manages withdrawal while helping to remove the toxic substances from an addict's body. Detoxification followed up by additional treatment is effective in long-term care of addicts.

Stein's study also shows that managed care patients may be doing better than some others when it comes to substance abuse treatment following detoxification.

The RAND researchers estimated the effect of co-payments of $30, $20, $10 and $0.

"The average co-payment for the patients we studied was $12.30. If co-payments were constant at $30 for all patients, we would see a 43 percent increase in the number of subjects not participating in follow-up. Co-payments of $20 would result in a 19 percent increase in non-participation," Stein said.

On the other hand, zero co-payment would see an increase in participation by 24 percent, and a $10 co-payment would result in a 5 percent increase in participation, Stein said.

This study also shows that managed care patients receive formal substance abuse treatment following inpatient detoxification at a "substantially higher" rate than that seen in populations that are not insured privately.

The length of time between detoxification discharge and follow-up for managed care patients was relatively brief, with most initial sessions occurring within one week and more than 90 percent occurring within two weeks.

—Paul Dingsdale

Volunteer some information: Who's a 'Good Neighbor'?

Nominations are requested for the 2000 USC Good Neighbors Volunteer Awards, to be presented at the Annual Volunteer Recognition Banquet on April 12.

The awards recognize individuals who are making a difference in the neighborhoods closest to the USC University Park Campus or the USC Health Sciences Campus through their volunteer efforts.

The categories are: Community Resident Volunteer; Non-Resident Volunteer; USC Staff Volunteer; USC Faculty Volunteer; and USC Alumni Volunteer. Honorees will receive a plaque and will designate a $250 donation to a non-profit agency of their choice. The deadline for submission is Friday, March 3. Sponsored by USC External Relations.

For information please contact Samuel Mark or Helen Franco, at USC Civic and Community Relations, (213) 743-5480, smark@usc.edu and hfranco@usc,edu.

American Cancer Society kicks off 'Daffodil Days'

The American Cancer Society is sponsoring its 15th annual Daffodil Days flower sale fundraising campaign, with orders being accepted through February 25th. The daffodil, symbolizing the new life and hope of spring, is used by cancer organizations worldwide.

Those ordering flowers have the option to have them delivered to patients at USC/Norris Cancer Center.

Prices range from $10 for a small bouquet to $110 for an elaborate arrangement. Hundreds of volunteers will gather at florist shops to bundle and arrange the flowers for delivery the week of March 20th. Proceeds will benefit the society's programs for cancer patients and their families, as well as public education programs.

To place an order, call your department coordinator, or the San Gabriel Valley Cancer Society office at (626) 795-7774.

CLINIC: Project aids homeless, gives students experience

Continued from Page 1

clinics, and almost never see doctors who have access to any previous records."

As many as 600,000 people in the U.S. are homeless, Rongey said. Homeless adults have more injuries and illnesses than the general population, and 28 to 53 percent of them lack a regular source of care. To make matters worse, 26 percent of them suffer from chronic mental illness and 71 percent suffer from chronic substance dependence, according to a 1997 study of homeless Los Angeles residents. Tuberculosis and HIV infection are more prevalent, as well.

Students and their physician advisor, Kathryn Challoner, associate professor of clinical emergency medicine, are working on obtaining nonprofit status for the clinic project and securing an official relationship with the university.

"We look forward to its imminent opening," Challoner said.

Rongey said the project in development typifies service learning: it provides an insight into the homeless population, encourages continued volunteer medical service to the underserved, promotes an understanding of clinic management and emphasizes the importance of working with community organizations to best serve patients.

The project will provide a chance for medical students to see patients, practice taking histories, administer basic physical exams and health education and give screenings and counseling—all under the close supervision of a faculty physician.

"We hope that involved medical students would find joy, and perhaps purpose, in serving the underserved," said Rongey, who hopes to enter either emergency medicine or pediatrics. "By keeping this project student-run, we are also teaching our medical students that we have the capability to bring about positive change in our communities."

The access center will have a shelter within it, so the clinic will have an in-house base of patients, as well as patients walking in off the street. The students plan for the clinic to refer patients who need specialized medical care to LAC+USC Medical Center for further treatment and hope to exchange records of shared patients with the medical center and other appropriate health centers to ensure patients get good follow-up care. PATH's access center will provide transitional housing, job placement services and life skills education.

The USC Free Clinic Project will be located in a building on North Madison Avenue, which will be remodeled to house a homeless access center run by People Assisting the Homeless (PATH). The center also will feature a shelter.

Students also are looking forward to partnering with other organizations, including the USC School of Dentistry, to provide additional services such as dental care, HIV testing and women's exams.

The students said supportive faculty members include Ron Ben-Ari, associate chair of educational affairs for the Department of Medicine; Jeannie Brewer, clinical instructor in family medicine; Madeline Bruning, nurse educator in pediatrics; Donna Elliot, associate professor of clinical pediatrics and assistant dean of curriculum & student affairs, clinical education; Peter Katsufrakis, associate dean of student affairs at the Keck School; Ricardo Hahn, professor and chair of the Department of Family Medicine; William Mallon, associate professor and director of the residency program of emergency medicine; and Madeleine R. Stoner, professor of social work.

PATH and the Department of Family Medicine will sponsor the group, Persoon-Gundy said. "We've begun the process of applying for grants, and have received our first check," she said. "It's only for a small amount, but it's a beginning, and hopefully a sign of the willingness of the community to fund a project like this one."

Nonprofit groups just starting out find it difficult to get grants, Rongey said, so the group is looking for private donations as well.

—Alicia Di Rado

HSC Weekly

USC: *Time Magazine*'s College of the Year 2000

HSC Weekly is published on Fridays, except for academic holiday periods. Copies are distributed throughout the Health Sciences Campus, University of Southern California. It is written and produced by the staff of Health Sciences Public Relations. Permission to reprint articles with attribution is freely given.

Editor: Jon Nalick
Executive Director of Public Relations: Brenda Maceo
Vice President, University Public Relations: Martha Harris

Contributors: Paul Dingsdale, Alicia Di Rado, Alfred Kildow, Brenda Maceo, Jon Nalick, Lori Oliwenstein, LaCarol Pratt, Richard Stone, Mary Ellen Stumpfl and Carol Varma

323/442-2830
FAX: 323/442-2832
hscwkly@hsc.usc.edu
http://www.usc.edu/hsc/info/pr/

NCI announces cancer deaths plateau despite population growth

National Cancer Institute (NCI) Director Richard Klausner recently testified before the House Subcommittee on Labor that "for the first time, between 1996 and 1997, the total number of cancer deaths in the United States did not rise, despite a growing and aging population."

He also reported that "the decrease in overall cancer mortality rates first observed in the early 1990s are accelerating between 1995 and 1997, the latest year for which we have data."

Rates are a per capita measure of the burden of cancer given as a number per 100,000 and adjusted to account for the fact that the U.S. population is growing older on average. More than half a million Americans die of cancer each year.

Klausner also explained how the genetic discoveries of the Cancer Genome Anatomy Project, which created a comprehensive index of genes that are altered in various cancers, has led to emerging diagnostic tools like the Lymphochip. The Lymphochip is a customized microarray, slightly larger than a penny, which contains over 18,000 genes involved in the immune system and cancer development.

In a report in the Feb. 3 issue of *Nature*, researchers who developed the Lymphochip showed that molecular diagnosis enables the most common form of non-Hodgkin's lymphoma to be subdivided into two distinct diseases: one that responds well to standard chemotherapy and one that does not.

According to the scientists, this finding shows the future importance of defining the distinct molecular characteristics of tumors as a way to more accurately diagnose and treat cancer.

Full text of the statement submitted to the subcommittee is available at NCI's Web site at and from the NCI Press Office at (301) 496-6641. The online testimony includes links to NCI programs and resources mentioned in the statement.

Schools spur reading to celebrate life of Dr. Seuss

In his books' pages, a cat sports a hat, green eggs go great with ham and Horton hears a Who.

The late children's author Theodore Geisel, a.k.a. Dr. Seuss, would have been 96 on March 2, but his books of rhymes and silly characters carry on his legacy with generations of kids.

To commemorate his life, educators nationwide are sponsoring a celebration of reading that week called Read Across America—and book lovers on this campus can participate.

The National Education Association and Griffin Avenue Elementary School, one of the HSC partner schools, are holding a Read Across America event Thursday, March 2 that brings in adults from the community to read with children.

Caring adults are invited to take along their favorite children's book, or choose a book from the school library, and read to a classroom of students at Griffin Avenue School. Volunteers may read in English, Spanish or Chinese.

The school also will run a book fair during the week of Feb. 28. Anyone wishing to buy a book and donate it to the school's library can take a look at the school's wish list for ideas, said Margaret Just, Griffin principal.

Interested volunteers are invited to arrive at Griffin Avenue School, 2025 Griffin Ave., Los Angeles at 8:30 a.m. March 2. To confirm attendance, call Pat Parkhill or Sylvia Carrillo at Griffin Avenue School, 222-8131.

Campus Cruiser program gets new hours

Because of low ridership last year, the Department of Public Safety's campus cruiser program will no longer operate after 10 p.m. at the Health Sciences Campus. Under new hours starting Feb. 28, the program will run weekdays from 5 p.m. to 10 p.m.

In other parking and transportation news:

• Metrolink train riders who are paid USC employees may purchase their train passes via payroll deduction from the Transportation Office, KAM 120. Passes will be available at the will call box at the office. For more information, call 442-1201.

• Reminder: New parking passes have been available since October. Anyone still using an old, hard plastic permit can get a new version at the parking office.

NIH revises salary limitations on grants

The National Institutes of Health (NIH) has established new salary limitations on NIH grants, cooperative agreements and contracts. These limitations represent the maximum salary rates for which an individual may be paid from an NIH award, and are indexed to U.S. Government Personnel Executive Levels II and III salaries by federal fiscal year. (It is not, however, the executive level that determines which cap should be applied, but rather the fiscal year in which the award is made (see below):

FY 1999 Awards (Executive Level III)	
October 1, 1998 through December 31, 1999	$125,900
January 1, 2000 and beyond	$130,200
FY 2000 Awards (Executive Level II)	
October 1, 1999 through December 31, 1999	$136,700
January 1, 2000 and beyond	$141,300

These limitations represent the maximum salary rates for which an individual may be paid from an NIH award. Salaries paid from current awards can use these limitations depending on the fiscal year from which the award was made and the period in which the salary is earned. What this means is that if an individual whose salary (base rate) exceeds the applicable limitation is paid after January 1, 2000 from an award coming from fiscal year 1999 funds, the maximum rate at which that person may be paid from an NIH award would be $130,200. If that same person is paid after January 1, 2000 from an award coming from fiscal year 2000 funds, the maximum rate that person may be paid from an NIH award would be $141,300.

For a more complete explanation of the new salary caps, visit the NIH Web site and search for the January 7, 2000 NIH Guide, or use the following URL: *http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-011.html*

Awards available

Foundation	Announcement	Eligibility	USC Deadline	Purpose	Application Process
Burroughs Wellcome Fund	2000 Interfaces between the Physical/Chemical/Computational Sciences and the Biological Sciences. $$150K to $500K per year for five years.	U.S. and Canadian institutions that grant doctoral degrees are invited to propose predoc or postdoc training programs.	March 10, 2000	To support the development of interdisciplinary training programs for graduate and postdoc students coming from quantitative and theoretical backgrounds so they can bring different approaches and new ideas into the biological arena.	Submit application to Scientific Affairs, Richard Lolley, KAM 110. Visit www.bwfund.org
The Whitaker Foundation	Biomedical Engineering Research Grants 2000. $210K to $240K over three years.	PI's who hold faculty positions at Institutes of higher education in U.S. or Canada, including universities, colleges, and medical, dental, pharmacy and veterinary schools.	March 1, 2000, July 1, 2000, and November 1, 2000	Eligible faculty members who intend to establish academic careers in biomedical engineering or a closely linked field and who seek support for biomedical engineering research projects.	Work with Scientific Affairs, Richard Lolley, KAM 110. Must submit preliminary application. See also, www.whitaker.org
The Robert Wood Johnson Foundation	Investigator Awards in Health Policy Research 2000. Grants range from $100K to $250K from one to three years.	Call for applications. Applications are encouraged from investigators in a diverse, broad range.	April 7, 2000	Requests proposals to interpret, develop, or substantially advance ideas or knowledge that can improve health or health care policy in the U.S.	Submit LOI directly to funder. Also, visit www.ahsr.org/rwjf
The Donald E. and Delia B. Baxter Foundation	Request for Proposals 2000. $150K award for a one-to two-year period.	Open to junior faculty at USC in tenure-track positions in the Keck School of Medicine.	March 13, 2000 by 5:00 p.m.	Supporting cutting-edge research conducted by faculty who in the future, will be successful in attaining external funding.	Submit proposal directly to Scientific Affairs, Richard Lolley, KAM 110.

HSC Research Awards for December 1999

Principal Investigator(s)	Department	Sponsor	Title	Total Awarded
Jack Kern	Pharmacy	Pfizer, Inc.	Assessment of Candidemia Risk Factor Changes Over Time in Surgical Intensive Care Patients	$15,000
Bryan Langholz	Preventive Medicine	National Cancer Institute	Time Related Factors in Cancer Epidemiology	$1,343,247
Amy S. Lee	Cancer Center	American Cancer Society, Inc.	American Cancer Society Institutional Research Grant	$240,000
Adele Pillitteri	Nursing	Fuld (Helene) Health Trust	Educational Mobility	$50,000
Juergen Reichardt	Institute for Genetic Medicine	Childrens Hospital Los Angeles	Androgen-Metabolic Genes and Prostate Cancer Risk: A Molecular Epidemiologic Investigation	$32,630
Walter Wolf	Pharmacy	National Cancer Institute	Minority Predoctoral Fellowship Program	$24,832

Calendar

Friday, Feb 18

3 - 5 p.m. Molecular Biology of Cancer Seminar Series. "Stress Proteins," Amy Lee, USC. McKibben Hall, Room 256. Info: 442-2337

Saturday, Feb 19

9 a.m. Glaucoma: New Developments and State-of-the-Arts. "Glaucoma Implants Returning to the Past?" George Baerveldt, UCI, "Pearls and Pitfalls of the Ahmed Valve," Richard Hill, UCI, and "Evaluating Our Peer-Reviewed Literature," Don Minckler, USC. DEI, Third Floor Conf. Ctr. Info: 442-6427

Tuesday, Feb 22

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

11 a.m. Division of Endocrinology and Diabetes Grand Rounds. "Hyponatremia," Marshall Fichman, USC. AHC Aud., Room 102. Info: 442-5100

12:15 p.m. Tuesday Speakers Forum. Grand Rounds - Adult Outpatient Psychiatry. "Clinical Case Presentation: Obsessive-Compulsive Disorder," Rhonda Bernardez, Donna Yi, and Steven Kingsbury, USC. AHC Aud., Room 102. Info: 226-4945

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "Thyroid Disease," Peter Singer USC, "Mood Disorders," Pamela Kushner, UCI, "Asthma," Richard Barbers, USC. DEI 3rd Floor Conf. Room. Info: 442-3443

Wednesday, Feb 23

7 a.m. Department of Medicine Grand Rounds. "Hyperthyroidism and Liver Disease," Jonathan Lopresti, USC. GNH 1645. Info: 226-7591

3 p.m. Molecular Biology of Cancer Seminar Series. "Epigenetics," Peter Laird, USC. McKibben Hall, Room 256. Info: 442-2337

4 p.m. Neural Information and Behavioral Sciences Seminar. "Goal-Directed Instrumental Action: Contingency, Incentive, Learning, and their Neural Substrates," Bernard Balleine, UCLA. Hedco Aud., UPC. Info: (213) 740-9176

Thursday, Feb 24

5 p.m. Neurology Conference. "Infectious Disease," Leslie Weiner, USC. KAM 308. Info: 226-2639

Friday, Feb 25

8:30 a.m. Research Seminar Series, Division of Pulmonary and Critical Care. "Organization and Regulation of the Epithelial Sodium Channel," Christie Thomas, Univ. of Iowa. GNH 11-321. Info: 442-1217

Noon. Molecular Biology Seminar. "Biochemical Basis of SOS-Induced Error-Prone Repair: E. Coli DNA Polymerase V: A Sloppier Copier," Myron Goodman, UCLA. Hedco Aud., UPC. Info: (213) 740-9176

3 p.m. Molecular Biology of Cancer Seminar Series. "Metastasis," Peter Brooks, USC. McKibben Hall, Room 256. Info: 442-2337

Saturday, Feb 26

9 a.m. Department of Surgery Grand Rounds. "Aortic Stent Grafts," Douglas Hood, USC. AHC Aud., Room 102. Info: 442-5910

Monday, Feb 28

11:30 a.m. "Preliminary Studies on the Role of FLIP in Inhibiting the Death of Prostate Epithelial Cells," John Krolewski, UCI. AHC Aud., Room 102. Info: 442-1145

Tuesday, Feb 29

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

11 a.m. Division of Endocrinology and Diabetes Grand Rounds. "Diabetic Infections," Alice Bessman, Rancho Los Amigos National Rehab. Ctr. AHC Aud., Room 102. Info: 442-5100

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "New Drugs for 2000: Part I and Part II," Gregory Thompson, USC. DEI 3rd Floor Conf. Room. Info: 442-3443

Wednesday, March 1

3 p.m. Molecular Biology of Cancer Seminar Series. "Angiogenesis," Peter Brooks, USC. McKibben Hall, Room 256. Info: 442-2337

Friday, March 3

Noon. Molecular Biology Seminar. "Predicting Highly Expressed Genes in Diverse Genomes," Samuel Karlin, Stanford, Univ. Hedco Aud., UPC. Info: (213) 740-7766

Noon. "Gene Therapy Using Hematopoietic Stem Cells," Donald Kohn, CHLA. Norris Tower 7th Floor Conf. Ctr. Info. 442-2337

Noon. Enviromental Health Sciences Center Monthly Seminar. "DNA Methylation," Peter Jones, USC. Norris Tower 4th Floor Conf. Ctr. Info: 442-1096

3:30 p.m. ""Pharmacophore-Based Design, Synthesis and Biological Testing of New Schiff Bases of Hydroxysemicarbazide as Antitumor Agents," Shijun Ren, USC. PSC 104. Info: 442-1451

Tuesday, March 7

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "Adolescent Medicine," Lawrence Neinstein, USC, "Chronic Fatigue and Fibromyalgia," Jimmy Hara, UCLA, "Cosmetic Surgery Update," Robert Kotler and Les Bolton, UCLA. DEI 3rd Floor Conf. Room. Info: 442-3443

Wednesday, March 8

3 p.m. Molecular Biology of Cancer Seminar Series. "Hormonal Carcinogenesis," Malcolm Pike, USC. McKibben Hall, Room 256. Info: 442-2337

Friday, March 10

3 p.m. Molecular Biology of Cancer Seminar Series. "Mouse Models of Cancer," Robert Maxson, USC. McKibben Hall, Room 256. Info: 442-2337

Tuesday, March 14

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "Screening and Treatment of Prostate Cancer," Eila Skinner, USC, "Treatment and Management of Obesity," Gary Anthone, USC, "Geriatric Evaluation and Assessment," Katherine Schlaerth, USC. DEI 3rd Floor Conf. Room. Info: 442-3443

Tuesday, March 21

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "Treatment and Management of Musculoskeletal Pain," Glenn Ehresmann, USC, "Cognitive Tissue Disorder," Daniel Arkfeld, USC, "Domestic Violence," Jean Forman, USC. DEI 3rd Floor Conf. Room. Info: 442-3443

Wednesday, March 22

3 p.m. Molecular Biology of Cancer Seminar Series. "Bladder Cancer," Peter Jones, USC. McKibben Hall, Room 256. Info: 442-2337

Friday, March 24

3 p.m. Molecular Biology of Cancer Seminar Series. "Prostate Cancer," Gerry Coetzee, USC. McKibben Hall, Room 256. Info: 442-2337

Tuesday, March 28

8:45 a.m. New Staff Orientation. KAM 308. Info: 442-1010

6:30 - 10 p.m. Common Problems in Primary Care, Annual Review Course. "Menopause and Hormone Replacement Therapy," Raquel Arias, USC, "Contraception and Cardiovascular Disease," Paul Brenner, USC, "Pap Smear and Cancer in Women," Susana Gonzalez, USC. DEI 3rd Floor Conf. Room. Info: 442-3443

Wednesday, March 29

3 p.m. Molecular Biology of Cancer Seminar Series. "Liver Cancer," Ron Ross, USC. McKibben Hall, Room 256. Info: 442-2337

Notice: Deadline for calendar submission is 4 p.m. Tuesday to be considered for that week's issue. Please note that timely submission does not guarantee an item will be printed. Send calendar items to *HSC Weekly*, DEI 2510 or fax to 442-2832, or e-mail to hscwkly@hsc.usc.edu. *Entries must include day, date, time, title of talk, first and last name of speaker, affiliation of speaker, location and a phone number for information.*

USC Health Sciences
Public Relations
1450 San Pablo Street
DEI 2510
Los Angeles, CA 90033

Non-Profit Organization
U.S. POSTAGE PAID
University of Southern
California